Zacks Investment Research lowered shares of Nu Skin Enterprises (NYSE:NUS) from a hold rating to a sell rating in a research note published on Wednesday morning.

According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “

Separately, ValuEngine upgraded shares of Nu Skin Enterprises from a hold rating to a buy rating in a research note on Tuesday, November 14th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $62.00.

Nu Skin Enterprises (NYSE:NUS) traded up $2.10 during trading on Wednesday, reaching $69.97. 530,822 shares of the company’s stock traded hands, compared to its average volume of 388,864. The firm has a market cap of $3,800.00, a price-to-earnings ratio of 25.63, a PEG ratio of 2.47 and a beta of 1.57. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.44. Nu Skin Enterprises has a 1 year low of $47.10 and a 1 year high of $70.27.

Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.76 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.76. The firm had revenue of $563.70 million for the quarter, compared to analyst estimates of $562.70 million. Nu Skin Enterprises had a net margin of 6.97% and a return on equity of 22.38%. The company’s revenue for the quarter was down 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.98 EPS. research analysts expect that Nu Skin Enterprises will post 3.23 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 6th. Shareholders of record on Friday, November 17th were paid a $0.36 dividend. The ex-dividend date of this dividend was Thursday, November 16th. This represents a $1.44 annualized dividend and a yield of 2.06%. Nu Skin Enterprises’s dividend payout ratio is presently 52.75%.

In other news, President Ryan S. Napierski sold 11,667 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $63.84, for a total transaction of $744,821.28. Following the transaction, the president now owns 71,634 shares in the company, valued at approximately $4,573,114.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Steven Lund sold 108,132 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $68.81, for a total transaction of $7,440,562.92. Following the transaction, the chairman now owns 4,769 shares in the company, valued at approximately $328,154.89. The disclosure for this sale can be found here. In the last quarter, insiders sold 218,732 shares of company stock worth $14,599,287. Company insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of Nu Skin Enterprises by 3.3% during the 2nd quarter. US Bancorp DE now owns 2,032 shares of the company’s stock worth $128,000 after purchasing an additional 65 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Nu Skin Enterprises during the 3rd quarter worth $148,000. Texas Yale Capital Corp. bought a new stake in shares of Nu Skin Enterprises during the 2nd quarter worth $217,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Nu Skin Enterprises during the 3rd quarter worth $219,000. Finally, Shelton Capital Management bought a new stake in shares of Nu Skin Enterprises during the 2nd quarter worth $232,000. Institutional investors own 77.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Nu Skin Enterprises (NUS) Rating Lowered to Sell at Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/nu-skin-enterprises-nus-rating-lowered-to-sell-at-zacks-investment-research/1781505.html.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with Analyst Ratings Network's FREE daily email newsletter.